For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Centene Corp. (CNC) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-08): Designation Bounce · Gem Score +4 (−100…+100 Quality+Value blend) · Quality -22 · Value 25 · Sentiment 27 (timing only, not weighted) · Composite fair value $92.37 vs $65.47 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Centene Corp.
CNC NYSECentene Corp. is a managed care and healthcare services company that focuses on government-sponsored and commercial health programs across the United States. Centene provides affordable, quality-focused coverage and related services primarily through Medicaid, Medicare, and Health Insurance Marketplace plans, serving individuals, families, and underserved populations. The company also offers specialized healthcare solutions that support care coordination, pharmacy benefits, behavioral health, dental, vision, and other managed services. Through a local-market approach, Centene works with health plans, providers, and public programs to help members access coverage and care tailored to community needs. Headquartered in St. Louis, Missouri, Centene plays a significant role in the U.S. healthcare market by administering large-scale managed care products and serving as a key intermediary in publicly funded healthcare systems.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -13.53
Total Equity: $20.06B
Shares: 493,116,000
Total Debt: $17.40B
Cash: $17.89B
EBITDA: -$6.35B
Total Debt: $17.40B
Cash: $17.89B
Revenue: $194.78B
Shares: 493,116,000
Revenue: $194.78B
Revenue: $194.78B
Revenue: $194.78B
Total Equity: $20.06B
Tax Rate: 0.8%
Equity: $20.06B
Total Debt: $17.40B
Cash: $17.89B
Current Liabilities: $36.70B
Long-Term Debt: $17.35B
Total Debt: $17.40B
Total Equity: $20.06B
Shares: 493,116,000
Shares: 493,116,000
CapEx: -$767.00M
Shares: 493,116,000
Stock Price: $65.47
Net Income: -$6.67B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 26, 2026 11:50pm (42d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $126.0B | $144.5B | $154.0B | $163.1B | $194.8B |
| Cost of Revenue | $111.5B | $127.6B | $136.4B | $146.0B | $180.6B |
| Gross Profit | $14.5B | $16.9B | $17.6B | $17.1B | $14.2B |
| Operating Expenses | $12.7B | $15.6B | $14.7B | $13.9B | $21.8B |
| Operating Income | $1.8B | $1.3B | $2.9B | $3.2B | -$7.6B |
| Net Income | $1.3B | $1.2B | $2.7B | $3.3B | -$6.7B |
| EBITDA | $3.3B | $2.9B | $4.2B | $4.4B | -$6.3B |
| EPS | $2.31 | $2.09 | $4.97 | $6.33 | $-13.53 |
| EPS (Diluted) | $2.28 | $2.07 | $4.95 | $6.31 | $-13.53 |
Balance Sheet (Annual)
Last updated: Aug 26, 2026 11:30pm (42d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $13.1B | $12.1B | $17.2B | $14.1B | $17.9B |
| Total Current Assets | $28.5B | $30.1B | $40.8B | $38.0B | $40.4B |
| Total Assets | $78.4B | $76.9B | $84.6B | $82.4B | $76.7B |
| Current Liabilities | $25.8B | $28.5B | $36.7B | $34.3B | $36.7B |
| Long-Term Debt | $18.6B | $17.9B | $17.7B | $18.4B | $17.4B |
| Total Liabilities | $51.4B | $52.6B | $58.7B | $55.9B | $56.7B |
| Total Equity | $27.0B | $24.2B | $26.0B | $26.5B | $20.1B |
| Retained Earnings | $8.1B | $9.3B | $12.0B | $15.3B | $8.7B |
Cash Flow (Annual)
Last updated: Aug 26, 2026 11:50pm (42d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $4.2B | $6.3B | $8.1B | $154.0M | $5.1B |
| Capital Expenditure | -$910.0M | -$1.0B | -$799.0M | -$644.0M | -$767.0M |
| Free Cash Flow | $3.3B | $5.3B | $7.3B | -$490.0M | $4.3B |
| Acquisitions (net) | -$534.0M | -$1.5B | $0 | $0 | — |
| Net Debt Issued / (Repaid) | $1.8B | -$1.1B | $19.0M | $678.0M | -$1.1B |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$297.0M | -$3.1B | -$1.6B | -$3.1B | -$475.0M |
| Net Change in Cash | $2.3B | -$868.0M | $5.2B | -$3.3B | $3.9B |
Growth Trends (YoY %)
Last updated: Aug 26, 2026 11:50pm (42d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +14.7% | +6.5% | +5.9% | +19.4% |
| Gross Profit Growth | +16.8% | +4.2% | -3.2% | -16.8% |
| Operating Income Growth | -26.1% | +122.3% | +8.4% | -340.1% |
| Net Income Growth | -10.8% | +124.8% | +22.3% | -301.9% |
| EBITDA Growth | -11.9% | +47.1% | +4.6% | -243.8% |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-10-03 02:02A +1σ run of quarters pays -350%; a −1σ run costs 100%. Ratio -3.5:1 (μ 12.5%, σ 6.8% , 16 pairs).
Older method (repeat-worst-quarter): 10.8 : 1
| Case | Growth | Margin | Fair value | vs price ($65.47) |
|---|---|---|---|---|
| Bull — recovery | +14% | 17.3% | $771.13 | +1078% |
| Base — stabilizes | +9% | 15.0% | $576.37 | +780% |
| Bear — keeps slipping | +5% | 12.8% | $418.42 | +539% |
| Stress — last quarter repeats | +22% | -2.5% | $0.00 | -100% |
| Upside — a +1σ run of quarters (v2) | +19% | -2.7% | $-163.74 | -350% |
| Stress — a −1σ run of quarters (v2) | +6% | -2.5% | $0.00 | -100% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-27 00:50The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Looking at the raw numbers first: Centene did $194.8B in 2025 revenue (up 19.4% YoY) but posted a $6.67B net loss driven overwhelmingly by Q3 2025's $6.63B single-quarter loss — that's the tell. Q1 and Q2 2026 have already snapped back to $1.54B and $1.09B in net income on $50-54B revenue runs, annualizing to roughly $5B+ in earnings. Gross profit collapsed from $17.07B in 2024 to $14.21B in 2025 on $32B more revenue — that's real MLR deterioration, not just a goodwill charge. But gross margin at 7.3% blended masks the recovery: if 2026 H1 margins hold, we're looking at a business generating $4-5B in net income against a $32B market cap, i.e., ~7x forward earnings. FCF of $4.32B against EV of ~$32B (cash roughly offsets debt) is a 13% FCF yield. The balance sheet is fine: $17.9B cash vs $17.4B debt, 1.1x current ratio, $20B equity.
The synthesis verdict ("High Conviction Required") and Market Forces ("Strong Market Headwinds — avoid") are in direct tension, and I think Market Forces is fighting the last war. Q3 2025 was the kitchen-sink quarter — reserve strengthening, likely PDR (premium deficiency reserve) accruals, and probably risk-adjustment true-ups from the ACA marketplace book. The two subsequent quarters returning to 2-3% net margin is exactly the pattern you'd expect from a one-time cost re-baseline, not "structural collapse." The bear thesis of "state contract losses accelerating" is not visible in the revenue line — Q2 2026 revenue of $53.6B is a record and up 10% from Q2 2025. The Pre-Flight note is correct that this is a traditional regulated business misclassified as "pre_profit_growth" by the rule engine (confidence 0.37 tells you the classifier itself is unsure); the anomaly warnings about profit metrics being lagging indicators are exactly backwards here — profit *recovery* is the leading signal, and it's already happening.
The contrarian case I'd steelman: managed Medicaid pricing is set annually with states, and if 2025's MLR blowout was caused by acuity mix shifts from redetermination (healthier members leaving, sicker ones staying), then 2026 rate resets should — and apparently did — restore margin. But if it was ACA marketplace adverse selection (Centene's Ambetter book grew aggressively in 2023-24), the 2026 open enrollment and subsidy cliff (enhanced APTCs expiring end of 2025) could bring another leg down. The 47,603-share insider sale in August 2026 is small ($3M-ish) and not thesis-breaking but worth noting nobody's buying either. Also, the "recent_revenue_yoy 19.4%" is partly inorganic/mix — some is Medicare Advantage growth, which is lower-margin than Medicaid was historically. So normalized net margin may be closer to 1.5-2% than the 2.0-2.6% run-rate implied by Q1-Q2 2026, which would peg earnings power at $3-4B, not $5B+.
Even hitting the conservative case — $3.5B normalized earnings — gets you to 9x P/E and ~10% FCF yield on a business with government-contracted revenue and no existential balance sheet risk. The market is pricing in the tail scenario (permanent 0-1% net margin or revenue decline) and giving zero credit to two consecutive quarters of recovery. I dissent from the "High Conviction Required" hedge and from Market Forces' "avoid" — the data has already turned. This is a mispriced recovery, not a broken company. Fair value at 12x $4B normalized earnings is $48B market cap, or ~$97/share, versus $65 today. Downside if ACA book re-implodes in 2026 H2 is probably $50. Asymmetry favors long, sized modestly given genuine tail risk around subsidy expiration.
GPT Reading
Centene does not read to me like a broken business so much as a damaged earnings statement attached to a still-functioning franchise. The rawest fact is that revenue kept climbing straight through the 2025 blowup: from $163.1B in 2024 to $194.8B in 2025, then to $49.9B and $53.6B in the first two quarters of 2026 versus $46.6B and $48.7B in the comparable 2025 quarters. That is roughly 7% YoY growth in Q1 2026 and 10% in Q2 2026 on an already huge base. If the core engine were truly in collapse, I would expect enrollment erosion or contract losses to show up first in sales; instead, what shows up is margin violence. 2025 swung from a $3.3B profit in 2024 to a $6.7B loss on nearly $32B more revenue, with the worst quarter a staggering -$6.6B net loss in Q3 2025 on $49.7B of sales. Yet the subsequent quarters matter more than the annual headline now: Q4 2025 was still negative at -$1.1B, but Q1 2026 rebounded to $1.54B and Q2 2026 held at $1.09B. That sequence looks much more like a company absorbing a major reset than one in an ongoing earnings death spiral.
The market is valuing Centene at just 0.17x sales and about 1.6x book despite a balance sheet that is not screaming distress. Cash of $17.9B slightly exceeds debt of $17.4B, current ratio is 1.10, and 2025 still produced $5.1B of operating cash flow and $4.3B of free cash flow despite the disastrous GAAP loss. For an actual meltdown story, I would expect either leverage stress or cash burn; neither is present here. The contradiction that stands out is between the “pre-profit growth” style machine labels and the economics of the company. This is not a speculative turnaround with unproven unit economics. It is a low-margin managed-care operator that normally earns 1-3% net margins and had one year where that margin fell to -3.4%. If Centene merely gets back to something like its 2023-2024 earnings power—say $2.7B-$3.3B of net income—today’s $32.3B market cap implies roughly 10x-12x normalized earnings for a business still growing revenue high single digits. That is not heroic underwriting; it is a recovery to where it just was.
My read, then, is moderately bullish: the stock is discounting a permanence of damage that the 2026 quarterly recovery does not yet support. The quarterly net margins in 2026 of 3.1% and 2.0% are entirely recognizable for this business, and if annualized they point to positive earnings power well above what the current multiple implies. Even gross profit data support caution rather than despair: gross profit fell from $17.1B in 2024 to $14.2B in 2025 despite higher revenue, so something definitely broke in the cost structure, but not enough to stop cash generation or top-line momentum. In a business this large, even a 100-150 basis point margin repair has enormous earnings consequences. At $65.47, investors are paying a distressed multiple for what increasingly looks like a post-charge normalization story. I would not call it a screaming bargain because managed care can always spring another reserve surprise, but I do think fair value is higher, closer to the mid-$70s to low-$80s if 2026 can finish with clearly positive full-year earnings and sustained FCF.
The strongest case against this view is that I may be underestimating how structural the 2025 deterioration was. Gross margin collapsed from 10.5% in 2024 to 7.3% in 2025, and operating income went from +$3.2B to -$7.6B; those are not tiny reserve wiggles. In healthcare plans, persistent medical cost inflation, poor pricing, adverse mix from Medicaid/Medicare, and state-contract pressure can make “temporary” margin damage last for years. The quarterly pattern also is not clean enough to declare victory: Q2 2025 was already negative, Q3 2025 catastrophic, Q4 still negative, and Q2 2026 earnings stepped down from Q1’s $1.54B to $1.09B despite higher revenue, implying margins remain fragile. The market may also be correctly punishing weak cash-flow quality: positive FCF during a loss year can reflect working-capital timing and insurance float dynamics more than durable owner earnings. If the true steady-state margin has reset from around 1.7%-2.0% net to closer to 0.5%-1.0%, then the stock is not cheap at all; it is merely optically cheap on sales.
What would change my mind is straightforward. If the next two quarters show revenue still around $50B but earnings slip back toward breakeven or losses, that would tell me 2026’s first-half recovery was just noise and that the market’s skepticism is justified. Likewise, if full-year operating cash flow weakens materially from the $5.1B level while reserves or medical costs keep biting, I would move to fair-to-bearish quickly. On the other hand, if Centene strings together another two quarters of positive earnings with net margins holding at 2% or better and exits 2026 with something like $3B+ annualized net income power, then today’s valuation is too low and the stock should re-rate above $75 without requiring any multiple enthusiasm.
Grok Reading
The numbers that matter most are not the -$6.67B annual loss in 2025 but what sits underneath it. Centene still generated $5.09B of operating cash flow and $4.32B of free cash flow in the same year it booked a $7.62B operating loss, which is the signature of a large non-cash charge—almost certainly goodwill impairment and medical-cost reserve true-ups tied to Medicaid redetermination—rather than a business that stopped throwing off cash. Revenue marched from $163B in 2024 to $195B in 2025 and kept climbing into mid-2026 ($49.9B then $53.6B), a 19% recent year-over-year clip on a twelve-and-a-half percent multi-year CAGR. The two most recent quarters have already restored positive earnings power: $1.54B net income at 3.1% margin in Q1 2026 and $1.09B at 2.0% in Q2. At $65.47 the equity is valued at $32.3B, or 0.17× sales and roughly 7.5× trailing FCF, with a net-cash balance sheet ($17.9B cash against $17.4B debt). That is a distress multiple on a franchise that is still growing the top line at double digits and has already printed two consecutive profitable quarters after the wipeout.
The market is therefore pricing Centene as if the 2025 collapse is the new normal rather than a one-time reset. Pre-impairment the company earned $2.7–$3.3B of net income on mid-single-digit operating margins; even a partial return to a 1.5–2.0% net margin on a $200B+ revenue base would produce $3–4B of earnings and support a far higher equity value. Gross margin compressed to 7.3% in the loss year from the mid-teens historically, yet the cash conversion remained intact and the balance sheet never required external capital. Insider activity is noise (small awards and one modest sale), not a signal of flight. The quantitative models that flag “pre-profit growth” and negative PE/EV-to-EBITDA are simply describing the accounting hangover; they are not describing a company that has lost its revenue engine or its liquidity.
The strongest counter-case is that the loss was not purely one-time and that medical-loss-ratio pressure is structural. FCF CAGR is already –22.8%, quarterly revenue growth is decelerating, and the company still lags sector peers on every profitability metric. State Medicaid contracts can be lost in a single RFP cycle, Medicare Advantage competition is intensifying, and a second year of sub-2% margins would leave the equity correctly cheap rather than mispriced. The Q3 2025 –$6.63B hole was large enough that residual adverse selection or reserve under-estimation could still surface. If medical cost inflation stays elevated and specialty-services attach rates fail to offset it, the 0.17× sales multiple becomes a value trap, not a bargain. I weigh this less heavily because the cash-flow statement already contradicted the income-statement disaster and because two clean quarters of 2–3% net margins have appeared; still, the risk is real and explains why the stock has not re-rated.
I would flip to neutral or bearish on a third consecutive quarter of negative net income, an MLR print that pushes operating margin back below zero, or the loss of a major state Medicaid contract that cuts revenue growth below mid-single digits. Conversely, two more quarters of ≥2.5% net margins and stable FCF above $1B per quarter would confirm the impairment thesis and force a re-rating toward 0.3–0.4× sales.
Qwen Reading local experiment · off-panel
The fact that decides this case is the Q3 2025 net loss of $6.63B sitting inside an otherwise profitable five-year history: 2021 NI $1.35B, 2022 $1.20B, 2023 $2.70B, 2024 $3.31B, then 2025's $6.67B hole. That single quarter is 10x the normal quarterly run-rate and is almost certainly a non-cash charge (impairment, reserve true-up), confirmed by the fact that operating cash flow for the full year was still positive at $5.09B and FCF at $4.32B. The "pre_profit_growth" classification in the canonical metrics is simply wrong — Centene is a $195B-revenue, four-of-five-years-profitable managed-care plan, not a pre-revenue startup. The negative P/E, negative EV/EBITDA, and negative ROE/ROIC are all artifacts of that one quarter, not a structural state.
Stripping the Q3 2025 outlier, the clean earnings run-rate is $2.7–3.3B (2023–2024), and the 2026 print is already tracking above that: H1 2026 net income is $2.63B ($1.54B in Q1 + $1.09B in Q2), which annualizes to roughly $5B if H2 holds, though I would discount for seasonality and the Q4 2025 loss of $1.10B that suggests the MLR problem bled into a second quarter. A conservative 2026E net income of $3.5–4.0B is defensible. Revenue grew 19.4% YoY to $194.78B, and the four-year revenue CAGR is 12.5% — this is a growing business, not a shrinking one. The "decelerating revenue" tag in the secondary signals is not supported by the quarterly print, which shows monotonic growth from $46.6B (Q1 2025) to $53.6B (Q2 2026).
The EV bridge is the cleanest way to see what the market is paying. Market cap $32.34B, cash $17.89B, debt $17.40B — net cash is essentially zero ($49M), so EV ≈ $31.9B. Against 2025 FCF of $4.32B, that is 7.4x. Against a normalized $3.5B net income, that is 9.1x. Against $195B revenue, that is 0.16x. For a healthcare plan with 12%+ revenue growth, a net-neutral balance sheet, and 2%+ normalized net margins, 7.4x FCF and 1.6x book (P/B of 1.61) are at the cheap end of the sector's 10–15x earnings / 2–4x book regime. The Valuation Synthesis's "0.2x P/S embeds extreme pessimism" is directionally right but understates the point: the market is pricing Centene as if the 2025 loss is the new normal, when the 2026 quarters say otherwise.
The strongest case against my read is the Q4 2025 loss of $1.10B, which means the MLR deterioration was not confined to a single impairment quarter. A smart bear would also point to the "Lagging Sector Peers" tag, the Medicaid redetermination overhang that the Narrative layer flags, and the fact that the 2025 operating loss of $7.62B (versus +$3.18B in 2024) implies a $10.8B swing in operating income — even if non-cash, it signals that medical cost ratios are under pressure and the company's local-market playbook is not generating the operating leverage the bull story assumes. The FCF CAGR of −22.8% over five years, while partly a base-year artifact, does confirm that cash generation has not kept pace with revenue growth, which is the hallmark of a plan whose MLR is drifting. I weigh this differently because the 2026 H1 earnings recovery is already in the tape, and the FCF of $4.3B in the loss year tells me the cash engine is intact even when GAAP earnings are not.
What would change my mind: a Q3 2026 print that shows net income below $500M or a second quarter of negative earnings would confirm the MLR problem is structural, not a one-time reserve event, and I would cut my fair value to the low $50s. Conversely, a Q3 2026 net income above $2B with MLR commentary showing stabilization would push me toward the upper end of my range and raise conviction. The specific number to watch is the medical cost ratio on the earnings call, not the GAAP bottom line, because the bottom line will keep being noisy with reserve adjustments.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Centene is a mega-scale government-sponsored health plan operator (Medicaid, Medicare, Marketplace) that grew revenue from $125.98B in 2021 to $194.78B in 2025, a roughly 55% cumulative expansion. But 2025 marks a rupture: gross margin fell from 10.5% to 7.3%, operating margin flipped from +1.9% to -3.9%, and the company printed a $6.67B net loss after four years of positive earnings. This is the classic managed-care medical-loss-ratio blowout pattern - premium pricing lagging cost trend, likely tied to Medicaid redeterminations and Marketplace risk-pool deterioration. On the plus side, cash generation held up ($4.32B FCF in 2025 after a $-490M FCF dip in 2024), OCF/NI of 2.12x and accruals at -5.6% of assets suggest the loss is not being masked - if anything the loss is fully cash-substantiated. Balance sheet is respectable: $20.32B liquid cash, $2.92B net cash, Altman Z 2.77 (grey but not distressed). Capital discipline is a genuine strength: diluted shares fell from 590.5M to 493.1M (-4.4% CAGR), SBC is negligible at 0.1% of revenue, and buyback/SBC ratio of 807% shows real per-share value concentration rather than the cosmetic buybacks common at this scale. The concern is that the underlying business quality just deteriorated sharply and it is unclear whether 2025 is a one-year repricing air-pocket or a structural margin reset in a business that already ran on thin 1-2% operating margins.
Verify before trusting this (6)
- Medical loss ratio (MLR) by segment (Medicaid, Medicare, Marketplace) in the 2025 10-K to isolate where the underwriting miss occurred
- Management guidance on 2026 rate adequacy and whether state Medicaid rates are being repriced to cover acuity from redeterminations
- Composition of the $20.32B liquid cash - how much is regulated statutory capital at subsidiaries vs freely deployable at HoldCo
- Reserve development disclosures - are prior-year reserves being strengthened, which would signal reserving was too optimistic
- Any goodwill/intangible impairment charges embedded in the 2025 loss vs pure operating deterioration
- Regulatory / DOJ / state overpayment litigation exposure that may have contributed to the loss
Centene's $32B market cap sits against a business that generated $3.3B of net income in 2024 before collapsing to a $6.7B GAAP loss in 2025 driven by a roughly $10B one-time hit. Strip that and normalized earnings power is plausibly in the $4-6/share range, putting the stock on a mid-single-digit normalized P/E versus a managed-care peer group historically at 12-15x. The composite fair value read of 'distress multiples for a Medicaid giant' aligns with this - the market is pricing meaningful permanent impairment to underwriting margins, not just a bad year.
Verify before trusting this (4)
- 2026 guidance for MLR and adjusted EPS on Q4 call
- Segment detail on which state contracts drove the underwriting loss and whether rates have been repriced
- Whether the $10B loss contains further reserve strengthening or is truly one-time
- Medicare Advantage star ratings and 2026 bid outcomes
The pressure on CNC right now is modestly positive and driven almost entirely by narrative repair rather than macro. A fresh fair-value bump from 63.78 to 71.67 tied to margin-recovery calls, multiple Zacks screens flagging CNC as a value/growth/broker-favored pick, and a Rank 1 Strong Buy tag are stacking analyst tone in the tailwind column. That is meaningful for a name that has been under a Medicaid-unwinding cloud - the story is shifting from 'cliff' to 'trough with a path out,' and news flow over the last 72h reflects that pivot.
Verify before trusting this (4)
- Whether more sell-side analysts follow with target hikes tied to margin recovery
- Any MLR/utilization data point from peers that could crack or confirm the recovery narrative
- Sector rotation signal - if managed care catches a bid as a group, the tailwind strengthens
- Medicaid redetermination updates that could re-open the cliff narrative
The world is repricing government-sponsored health coverage. Post-COVID, the enrollee base is permanently larger than 2019 but politically contested: enhanced ACA subsidies lapsing, Medicaid work requirements and state budget stress all shrink the funded pool from here, while medical cost trend stays elevated. That combination turns Centene from a volume story into a rate-and-underwriting story. Macro is a second-order input for a payer — 4.64% ten-year modestly helps investment income on float, and there is no consumer-discretionary linkage. The decisive variables are legislative and actuarial, not economic.
When we made this prediction on Aug 27, 2026, CNC was $65.95. We expect it to be $62.50 by Feb 2027, and we consider it great value under $55.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 27, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.
Post-Report Due Diligence NOTES
Evidence for a closer look, not a verdict — no score or designation on this page has been changed by it. Items marked material are ones where a conclusion above moves to the other side of the price.